BIVI BioVie Inc.
Financings ·
BioVie agreed with A.G.P./Alliance Global Partners to sell up to $6,464,341 of Class A common stock through an at-the-market program, with a 3.0% commission on gross proceeds.
The 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible.
BioVie said bezisterim met its prespecified endpoints in early-stage Parkinson's disease, with improved blood inflammatory markers and better composite clinical outcomes than placebo.
ThinkEquity was sole underwriter for 5,620,000 units and 380,000 pre-funded units. Warrants carry a $2.50 exercise price and trade as BIVIW; BioVie plans to use the money for working capital.
BioVie priced 6,000,000 units, including pre-funded units, at $2.00 each for about $12 million. ThinkEquity is sole book-running manager, and the prospectus says the financial statements raise substantial doubt about the company's ability to continue as a going concern.
BioVie Inc. describes itself as a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its main program is bezisterim (NE3107), an investigational oral small molecule that the company believes inhibits inflammation-driven insulin resistance. The company is studying bezisterim in Alzheimer's disease, Parkinson's disease and Long COVID. In August 2026 BioVie announced topline results from its Phase 2b SUNRISE-PD trial, a randomized, double-blind, placebo-controlled study of bezisterim 20 mg twice daily in 57 patients with early-stage Parkinson's disease who were naive to symptomatic dopaminergic therapy. The company said the trial met its prespecified primary endpoint on a panel of blood-based inflammatory markers. It described bezisterim as well tolerated, while noting that the results are preliminary and that the biomarker endpoints are not validated surrogate endpoints. The company intends to use the results to inform the design of a potentially pivotal Phase 3 registrational trial in Parkinson's disease. Its earlier Phase 2 study in Parkinson's disease was completed in December 2022.
| Product or program | What it is | Stage |
|---|---|---|
| Bezisterim (NE3107) | Oral small molecule studied in Alzheimer's, Parkinson's and Long COVID | Phase 2b topline results reported |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $14.0 million | $9.3 million |
| Net income (loss) | -$22.1 million | -$17.5 million |
| Cash from operations | -$19.0 million | -$19.0 million |
| Cash and equivalents | $9.0 million | $17.5 million |
Our latest story on this, dated Aug 8, 2025: "BioVie prices $12 million public offering of units at $2.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 11, 2026: "BioVie enters sales agreement for up to $6,464,341 of common stock". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "BioVie securities class certified in Nevada; three derivative suits stayed". The story links the filing or release it is based on. Read the story.
BioVie Inc. trades under the ticker BIVI on NASDAQ.
BioVie Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for BioVie Inc. is 1580149. Its filings are on SEC EDGAR.
7,542,638 shares as of 2026-08-10, per the cover page of its 10-K filed 2026-08-13.
Our directory records BioVie Inc. under United States.
Our directory classifies BioVie Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BioVie Inc. is US09074F5044.
aibio.space lists BioVie Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
BioVie Inc. describes itself as a clinical-stage company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its main program is bezisterim (NE3107), an investigational oral small molecule that the company believes inhibits inflammation-driven insulin resistance.
Bezisterim (NE3107): Oral small molecule studied in Alzheimer's, Parkinson's and Long COVID Stage: Phase 2b topline results reported.
BioVie Inc. reported a net loss of $22.1 million for the fiscal year ended Jun 30, 2026, and used $19.0 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio